Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia

Annals of Hematology

Volumn 93, Issue 12, 2014, Pages 1977-1983

  Cornet, Edouard ^a   Delmer, Alain ^b   Feugier, Pierre ^c   Garnache Ottou, Francine ^d   Ghez, David ^e   Leblond, Véronique ^f   Levy, Vincent ^g   Maloisel, Frédéric ^h   Re, Daniel ^i,j   Zini, Jean Marc ^k   Troussard, Xavier ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g AVICENNE HOSPITAL   (France)

^h Saint Anne's clinic of Strasbourg   (France)

ⁱ Antibes Hospital   (France)

^j CENTRE ANTOINE LACASSAGNE   (France)

^k SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Diagnosis; Hairy cell leukaemia; Recommendations; Treatment

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; B RAF KINASE; BRAF PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; RITUXIMAB; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

B LYMPHOCYTE; BLOOD; DIFFERENTIAL DIAGNOSIS; EXON; FEMALE; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA, HAIRY CELL; LYMPHOMA, NON-HODGKIN; MALE; MUTATION; PATHOLOGY; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; SALVAGE THERAPY; SPLENIC NEOPLASMS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; EXONS; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IMMUNOPHENOTYPING; INTERFERON-ALPHA; LEUKEMIA, HAIRY CELL; LYMPHOMA, NON-HODGKIN; MALE; MUTATION; NEOPLASM PROTEINS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SALVAGE THERAPY; SPLENIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922245003     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2140-y     Document Type: Article

References (36)

1. Bernstein L, Newton P, Ross RK (1990) Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 50(12):3605–3609
2. Morton L, Wang S, Devesa S, Hartge P, Weisenburger D, Linet M (2006) Lymphoma incidence patterns by who subtype in the United States, 1992–2001. Blood 107(1):265–276. doi:10.1182/Blood-2005-06-2508
3. Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A (2009) Haematological malignancies: incidence in Basse-Normandie, France, for 1997–2004. Rev Epidemiol Sante Publique 57(3):151–158. doi:10.1016/J.Respe.2009.02.204
4. Chandran R, Gardiner SK, Smith SD, Spurgeon SE (2013) Improved survival in hairy cell leukaemia over three decades: a seer database analysis of prognostic factors. Br J Haematol 163(3):407–409. doi:10.1111/Bjh.12490
5. Clavel J, Hemon D, Mandereau L, Delemotte B, Severin F, Flandrin G (1996) Farming, pesticide use and hairy-cell leukemia. Scand J Work Environ Health 22(4):285–293
6. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foa R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315. doi:10.1056/Nejmoa1014209
7. Gopaluni S, Sanyal S, Bair A, Vajpayee N (2011) Hairy cell leukemia variant in a patient with chronic myeloid leukemia receiving nilotinib: sequential or coincidental? J Clin Oncol. doi:10.1200/Jco.2011.38.1392
8. Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D (1994) The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma 14(Suppl 1):57–61
9. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que T, Catovsky D (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8(10):1640–1645
10. Andrulis M, Penzel R, Weichert W, Von Deimling A, Capper D (2012) Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 36(12):1796–1800. doi:10.1097/Pas.0b013e3182549b50
11. Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S, Grigoriadis G, Westerman DA (2012) Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica 97(5):780–783. doi:10.3324/Haematol.2011.054874
12. Summers TA, Jaffe ES (2011) Hairy cell leukemia diagnostic criteria and differential diagnosis. Leuk Lymphoma 52(Suppl 2):6–10. doi:10.3109/10428194.2011.565435
13. Cawley JC, Burns GF, Hayhoe FG (1980) A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 4(6):547–559
14. Robak T (2011) Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 37(1):3–10. doi:10.1016/J.Ctrv.2010.05.003
15. Matutes E, Wotherspoon A, Catovsky D (2003) The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 16(1):41–56
16. Shao H, Calvo KR, Gronborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM (2013) Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res. doi:10.1016/J.Leukres.2012.11.021
17. Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P (2008) Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 111(4):2253–2260. doi:10.1182/Blood-2007-07-098848
18. Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F (2009) Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 114(21):4696–4702. doi:10.1182/Blood-2009-03-212449
19. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ (2009) VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 114(21):4687–4695. doi:10.1182/Blood-2009-01-201731
20. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O’Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145(6):733–740. doi:10.1111/J.1365-2141.2009.07668.X
21. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 156(2):186–195. doi:10.1111/J.1365-2141.2011.08931.X
22. Kreitman RJ, Polliack A, Grever M (2011) Treatment of hairy cell leukemia in its second half-century: an international conference on hairy cell leukemia at the National Institutes of Health, April 26–27, 2010, Bethesda, MD. Leuk Lymphoma 52(Suppl 2):1–2. doi:10.3109/10428194.2011.552478
23. Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M (2008) Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 143(2):296–298. doi:10.1111/J.1365-2141.2008.07333.X
24. Zenhausern R, Simcock M, Gratwohl A, Hess U, Bargetzi M, Tobler A, Swiss Group For Clinical Cancer R (2008) Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica 93(9):1426–1428. doi:10.3324/Haematol.11564
25. Forconi F, Cencini E, Sicuranza A, Sozzi E, Lauria F (2011) Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. Leuk Lymphoma 52(1):15–23. doi:10.3109/10428194.2010.530362
26. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. doi:10.1200/Jco.2011.38.1756
27. Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I (2011) Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma 52(Suppl 2):82–86. doi:10.3109/10428194.2011.565843
28. Dietrich S, Glimm H, Andrulis M, Von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366(21):2038–2040. doi:10.1056/Nejmc1202124
29. Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, Bench A, Wright P, Van’t Veer MB, Scott MA (2013) Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161(1):150–153. doi:10.1111/Bjh.12201
30. Lacouture ME, O’Reilly K, Rosen N, Solit DB (2012) Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol 30(3):329–330. doi:10.1200/Jco.2011.38.2895
31. Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98(2):E20–22. doi:10.3324/Haematol.2012.082404
32. Anforth R, Fernandez-Penas P, Long GV (2013) Cutaneous toxicities of RAF inhibitors. Lancet Oncol 14(1):E11–18. doi:10.1016/S1470-2045(12)70413-8
33. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366(3):207–215. doi:10.1056/Nejmoa1105358
34. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ (2013) Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 19(22):6313–6321. doi:10.1158/1078-0432.Ccr-13-1848
35. Sigal DS, Sharpe R, Burian C, Saven A (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 115(10):1893–1896. doi:10.1182/Blood-2009-10-251645
36. Ravandi F, Jorgensen JL, O’Brien SM, Verstovsek S, Ca K, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658–4662. doi:10.1182/Blood-2005-11-4590